Ganciclovir pharmacokinetics during renal impairment
نویسندگان
چکیده
منابع مشابه
Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment.
OBJECTIVES We investigated the pharmacokinetics of ganciclovir in 12 haematopoietic stem cell transplantation (HSCT) recipients to evaluate the validity of a 50% reduction in the ganciclovir dosage for mild renal impairment. PATIENTS AND METHODS Ganciclovir at 5 mg/kg/day was pre-emptively infused in patients with estimated CL(CR) > or = 70 mL/min (Group A), whereas the dose was reduced to 2....
متن کاملPharmacokinetics of Ganciclovir during Continuous Venovenous
ぬば ぬぱ Ganciclovir is an antiviral agent that is frequently used in critically ill patients with ぬひ cytomegalovirus (CMV) infections. Continuous venovenous haemodiafiltration (CVVHDF) is a ねど common extracorporeal renal replacement therapy in intensive care patients. Aim of this study ねな was to investigate the pharmacokinetics of ganciclovir in anuric patients undergoing CVVHDF. ねに Population ph...
متن کاملInsulin Degludec: Pharmacokinetics in Patients with Renal Impairment
BACKGROUND Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. METHODS Thirty subjects (n = 6 per group) received a single subcutaneous dose of 0.4 U/k...
متن کاملPharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
Two open-label, single-dose, parallel-group studies were conducted to characterize the pharmacokinetics of the novel antibacterial tedizolid and the safety of tedizolid phosphate, its prodrug, in renally or hepatically impaired subjects. Tedizolid pharmacokinetics in subjects with severe renal impairment without dialysis support was compared with that of matched control subjects with normal ren...
متن کاملEffect of renal impairment on the pharmacokinetics of exenatide
AIMS To evaluate the pharmacokinetics (PK), safety and tolerability of a single exenatide dose in patients with renal impairment (RI). METHODS Exenatide (5 or 10 microg) was injected subcutaneously in 31 subjects (one with Type 2 diabetes) stratified by renal function [Cockcroft-Gault creatinine clearance (CrCL), number of subjects]: normal (>80 ml min(-1), n = 8), mild RI (51-80 ml min(-1), ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Antimicrobial Agents and Chemotherapy
سال: 1988
ISSN: 0066-4804,1098-6596
DOI: 10.1128/aac.32.12.1899